The U.S. Food and Drug Administration (FDA) has approved Enhertu (fam-trastuzumab deruxtecan-nxki) in combination with Perjeta (pertuzumab) for the first-line treatment of adults with unresectable or ...
The Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki, or Enhertu from Daiichi Sankyo (DSNKY), in combination with pertuzumab ...
Human epidermal growth factor receptor 2 (HER2)/neu overexpression, amplification and mutations are associated with an increased metastatic potential in cancer cells and poor prognosis. HER2 signaling ...
The highest rates of HER2 positivity were observed in bladder cancer, uterine serous carcinoma, and esophagogastric junction cancer. New research suggests the incidence of HER2 positivity is low ...
FDA expands labels for Roche's PATHWAY HER2 (4B5) test* and VENTANA HER2 Dual ISH DNA Probe Cocktail, which can now be used to identify HER2-positive metastatic breast cancer patients that could be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback